IPHA_logo_main_version_h100IPHA_logo_main_version_h100IPHA_logo_main_version_h100IPHA_logo_main_version_h100
  • Home
  • #InnovateForLife
  • News
  • Events
    • IPHA Forum
    • IPHA Conference
    • All other events
  • Publications
    • 2025
      • Industry’s Role in Shaping Ireland’s Life Science Strategy
      • EFPIA Patients Wait Indicator 2024
      • IPHA Position Paper on Fairer and Faster Access to Medicine
    • 2024
      • EFPIA Patient WAIT Indicator Survey
      • Clinical Trials Agreement
      • Making Ireland a European Leader in Clinical Research
    • 2023
      • Achieving Universal Access to New Medicines for Irish Patients
      • Oireachtas briefing
      • IPHA Policy on Supply Outside Reimbursement Final
      • IPHA Self-Care Infographic
    • 2022
      • IPHA reimbursement timelines analysis 2022
      • Factors Affecting the Location of Biopharmaceutical Investments and Implications for European Policy Priorities
      • IHE Cancer Care Comparator Study
      • White Paper on Enterprise
    • 2021
      • Clinical Trials Survey
      • Cell and Gene Pathfinder Study
      • IPHA Codes of Practice
      • Agreement 2021
    • Pre 2020
      • BioPharma Ambition
      • Manifesto for Better Health
      • Innovation and the IP Framework
      • Self-Care: Taking Charge of Your Health
      • Vaccines For Life
      • Perspectives on Ireland’s Medicines Future
  • Submissions
    • 2025
      • IPHA Submission to Department of Foreign Affairs and Trade EU Presidency 2026
      • IPHA Life Science Strategy Submission Dec 25
      • IPHA Response LSS Consultation final 25
      • RD Incentives Consulation_Final 19 May 25
    • 2024
      • IPHA Submission National Rare Disease Strategy 2024
    • 2023
      • Expert Taskforce Submission September 2023 letter
      • Sinn Fein consultation paper Dec 23
  • Code
    • Codes of Practice
    • Transfers of Value
    • Mandatory notification regarding Advisory Board Meetings
    • IPHA Code Training
    • Complaints
  • Clinical & Regulatory
    • Regulation for Innovation
    • Clinical Trials
    • Medicine Safety
    • Regulatory Science Ireland
    • Counterfeit Medicines
  • Self-Care
  • About
    • Members
    • Board of Directors
    • Media Queries
    • Our Team
    • Affiliates Programme
    • Job Opportunities
  • Home
  • #InnovateForLife
  • News
  • Events
    • IPHA Forum
    • IPHA Conference
    • All other events
  • Publications
    • 2025
      • Industry’s Role in Shaping Ireland’s Life Science Strategy
      • EFPIA Patients Wait Indicator 2024
      • IPHA Position Paper on Fairer and Faster Access to Medicine
    • 2024
      • EFPIA Patient WAIT Indicator Survey
      • Clinical Trials Agreement
      • Making Ireland a European Leader in Clinical Research
    • 2023
      • Achieving Universal Access to New Medicines for Irish Patients
      • Oireachtas briefing
      • IPHA Policy on Supply Outside Reimbursement Final
      • IPHA Self-Care Infographic
    • 2022
      • IPHA reimbursement timelines analysis 2022
      • Factors Affecting the Location of Biopharmaceutical Investments and Implications for European Policy Priorities
      • IHE Cancer Care Comparator Study
      • White Paper on Enterprise
    • 2021
      • Clinical Trials Survey
      • Cell and Gene Pathfinder Study
      • IPHA Codes of Practice
      • Agreement 2021
    • Pre 2020
      • BioPharma Ambition
      • Manifesto for Better Health
      • Innovation and the IP Framework
      • Self-Care: Taking Charge of Your Health
      • Vaccines For Life
      • Perspectives on Ireland’s Medicines Future
  • Submissions
    • 2025
      • IPHA Submission to Department of Foreign Affairs and Trade EU Presidency 2026
      • IPHA Life Science Strategy Submission Dec 25
      • IPHA Response LSS Consultation final 25
      • RD Incentives Consulation_Final 19 May 25
    • 2024
      • IPHA Submission National Rare Disease Strategy 2024
    • 2023
      • Expert Taskforce Submission September 2023 letter
      • Sinn Fein consultation paper Dec 23
  • Code
    • Codes of Practice
    • Transfers of Value
    • Mandatory notification regarding Advisory Board Meetings
    • IPHA Code Training
    • Complaints
  • Clinical & Regulatory
    • Regulation for Innovation
    • Clinical Trials
    • Medicine Safety
    • Regulatory Science Ireland
    • Counterfeit Medicines
  • Self-Care
  • About
    • Members
    • Board of Directors
    • Media Queries
    • Our Team
    • Affiliates Programme
    • Job Opportunities
  • Home
  • About Us
  • Contact Us

Code

  • Home
  • Code
code-of-practice

Codes of Practice

tov

Transfer of Value

boardroom

Mandatory notification regarding Advisory Board Meetings

training-icon

IPHA Code Training

complaints

Complaints

Terms and Conditions    |    Privacy Statement   |   Sitemap    |    Cookies


Registered Number: 254776    |    Registered Address: 7 Clanwilliam Terrace, Dublin 2, D02 CC64 Ireland   |  Email: info@ipha.ie

© 2024 IPHA